Merial Limited v Novartis AG

Link copied
Case Copied 14 min read

IP AUSTRALIA

AUSTRALIAN PATENT OFFICE

Merial Limited v Novartis AG [2013] APO 65

Patent Application:                2010206029

Title:Palatable ductile chewable veterinary composition

Patent Applicant:                   Novartis AG

Opponent:  Merial Limited

Hearing Officer:  P M Spann, Deputy Commissioner of Patents

Decision Date:  5 December 2013

Hearing Date:  25 November 2013  

Catchwords:  PATENTS – extension of time to file evidence in answer – reg 5.9 – whether applicant has acted promptly and diligently at all times – whether circumstances beyond control – extension refused.

Representation:  Patent applicant:  M Caine, Davies Collison Cave

Opponent:M Caulfield, FB Rice

IP AUSTRALIA

AUSTRALIAN PATENT OFFICE

Patent Application:                2010206029

Title:Palatable ductile chewable veterinary composition

Patent Applicant:                   Novartis AG

Opponent:  Merial Limited

Date of Decision:                   5 December 2013

DECISION

Extension of time refused.

REASONS FOR DECISION

  1. This matter concerns a request for an extension of time to file evidence in answer and is determined under regulation 5.9 of the Patents Regulations as amended on 15 April 2013 by the Intellectual Property Legislation Amendment (Raising the Bar) Regulation 2013 (No 1).

    Background

  2. Patent application 2010206029 was filed by Novartis AG (Novartis) on 29 July 2010 as a divisional of 2008201605. The parent application was itself a divisional application. It was accepted and opposed but was withdrawn on 2 April 2013 after evidence in support of that opposition was filed.

  3. The present application was advertised as accepted on 9 August 2012 and a notice of opposition to the grant of a patent was filed in the name of Merial Limited (Merial) on 29 November 2012. A statement of grounds and particulars was served and filed on 31 January 2013 and the evidence in support completed on 27 April 2013.

  4. Consequently, the period for filing evidence in answer commenced on 27 April 2013 (the Commissioner’s letter in this regard is in error). However due to the operation of subregulation 23.26(2)(Item 4), the end of the period for filing evidence support became 29 July 2013.

  5. On 18 July 2013 the attorney for Novartis filed the first declaration made by its expert Dr James Rowe as part evidence in answer. It then filed on 29 July 2013 a request for an extension of time of three months to 29 October 2013. The reasons provided were essentially that, while significant progress had been made, Dr Rowe had gone on holiday for an extended period before the evidence could be completed.

  6. The extension was not objected to and a delegate of the Commissioner granted the extension on 14 August 2013 for the period requested.  On 24 October 2013 Novartis filed Dr Rowe’s 2nd, 3rd and 4th declarations as part evidence in answer. Then on 29 October 2013 Novartis filed the present request for an extension of time for an additional period of two months to 29 December 2013. A delegate on 1 November 2013 informed the parties that, subject to a party requesting to be heard, the Commissioner intended to grant the extension.

  7. Merial notified the Commissioner on 7 November 2013 that…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Merial Limited v Novartis AG and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2013] APO 65
Decision Date

CaseChat Overview and Summary

In the case of Merial Limited v Novartis AG, the applicant, Novartis AG, sought an extension of time to file evidence in answer to an opposition filed by Merial Limited. The opposition was filed against a patent application for a palatable ductile chewable veterinary composition. The court was required to determine whether Novartis had acted promptly and diligently in the preparation of its evidence in answer and whether there were exceptional circumstances that warranted the extension. The court considered the totality of Novartis's efforts to obtain the evidence, including the engagement of an expert, Dr James Rowe, who was known to be taking extended leave. The court found that Novartis had not acted promptly and diligently, particularly in persevering with Dr Rowe in the knowledge that he would be taking extended leave. The court also found that there were not exceptional circumstances that warranted the extension. The court concluded that the period for filing evidence in answer ended on 29 October 2013 and that the declarations filed on 18 and 27 November were not evidence in answer in relation to the opposition. Costs were awarded against the patent applicant, Novartis.

The decision of the court was that the extension of time sought by Novartis was refused. The court found that Novartis had not acted promptly and diligently in the preparation of its evidence in answer and that there were not exceptional circumstances that warranted the extension. The court directed that the period for filing evidence in reply commences from the date of this decision. The court also directed that the declarations filed on 18 and 27 November are not evidence in answer in relation to the opposition. Novartis may make an application for leave to file the declarations as further evidence under subregulation 5.10(4) as it existed before 15 April 2013. The court made no comment on the prospects of success for such an application other than that it will be considered on its merits. Otherwise, the declarations may be information that the Commissioner takes into account under regulation 5.11 as it existed before 15 April 2013. The court awarded costs in accordance with Schedule 8 of the Patents Regulations against the patent applicant Novartis.

Orders

Orders of the court

Full text does not contain this section.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

Full text does not contain this section.

Ratio Decidendi

Legal Principle Established

Full text does not contain this section.